GlassScriptPhysician profile
William M Dugan
NPI 1568434918
$571.30
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $316 · 2020: $205 · 2024: $49.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $49.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $49.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $224.95 | 2019 | |
| Astellas Pharma US INC | $128.84 | 2019-2020 | |
| Janssen Biotech, INC. | $89.93 | 2020 | |
| Celgene Corporation | $49.93 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $44.12 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $19.25 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.28 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Dugan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.